IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $24.48 and last traded at $24.93, with a volume of 96045 shares. The stock had previously closed at $25.59.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the stock. Leerink Partnrs cut shares of IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 5th. Citigroup reduced their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a "buy" rating for the company in a report on Tuesday, August 27th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research note on Tuesday. UBS Group started coverage on shares of IDEAYA Biosciences in a research report on Thursday, October 24th. They issued a "buy" rating and a $50.00 price target for the company. Finally, Wedbush restated an "outperform" rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $53.67.
Check Out Our Latest Stock Analysis on IDEAYA Biosciences
IDEAYA Biosciences Stock Down 3.1 %
The company's 50-day simple moving average is $28.49 and its 200 day simple moving average is $34.17. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of -10.64 and a beta of 0.79.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same period last year, the business earned ($0.46) earnings per share. On average, equities analysts expect that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current fiscal year.
Institutional Investors Weigh In On IDEAYA Biosciences
A number of hedge funds have recently bought and sold shares of the company. Allworth Financial LP lifted its holdings in shares of IDEAYA Biosciences by 800.0% during the third quarter. Allworth Financial LP now owns 900 shares of the company's stock worth $29,000 after buying an additional 800 shares during the last quarter. Covestor Ltd raised its stake in IDEAYA Biosciences by 23,050.0% during the 3rd quarter. Covestor Ltd now owns 926 shares of the company's stock valued at $29,000 after purchasing an additional 922 shares during the last quarter. Quest Partners LLC bought a new stake in IDEAYA Biosciences in the 2nd quarter valued at $41,000. US Bancorp DE grew its position in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company's stock worth $54,000 after purchasing an additional 689 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in shares of IDEAYA Biosciences by 637.9% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company's stock worth $68,000 after purchasing an additional 1,684 shares during the period. 98.29% of the stock is currently owned by institutional investors.
About IDEAYA Biosciences
(
Get Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
See Also
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
